1-8 of 8
Matteo Della Porta
Close
Sort by
Journal Articles

Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

Wolfgang Kern, Theresia M. Westers, Frauke Bellos, Marie C Bene, Peter Bettelheim, Lisa Eidenschink Brodersen, Kate Burbury, Sung-Chao Chu, Matthew Cullen, Matteo Della Porta, Alan Stewart Dunlop, Ulrika Johansson, Sergio Matarraz, Uta Oelschlaegel, Kiyoyuki Ogata, Anna Porwit, Frank W. M. B. Preijers, Katherina Psarra, Leonie Saft, Dolores Subirá, Elisabeth Weiss, Arjan A. Van de Loosdrecht
Journal: Blood
Blood (2021) 138 (Supplement 1): 3995.
https://doi.org/10.1182/blood-2021-152298
Published: 2021
Journal Articles

The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions

Matteo Della Porta, Uwe Platzbecker, Valeria Santini, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Rodrigo Ito, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140284
Published: 2020
Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD
Journal: Blood
Blood (2010) 116 (21): 2912.
https://doi.org/10.1182/blood.V116.21.2912.2912
Published: 2010
Journal Articles

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Norbert Gattermann, Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 3803.
https://doi.org/10.1182/blood.V114.22.3803.3803
Published: 2009
Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3806.
https://doi.org/10.1182/blood.V114.22.3806.3806
Published: 2009
Journal Articles

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)

Andrea Pellagatti, Eva Hellström-Lindberg, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo Della Porta, Martin Jädersten, Sally Killick, Davendra P. Sohal, Amit Verma, Mario Cazzola, James S. Wainscoat, Jacqueline Boultwood
Journal: Blood
Blood (2008) 112 (11): 3641.
https://doi.org/10.1182/blood.V112.11.3641.3641
Published: 2008
Journal Articles

Gene Expression Profiling of CD34 + Cells in Patients with Myelodysplastic Syndromes

Andrea Pellagatti, Mario Cazzola, Aristoteles Giagounidis, Janet Perry, Luca Malcovati, Matteo Della Porta, Martin Jädersten, Sally Killick, Eva Hellström-Lindberg, James S. Wainscoat, Jacqueline Boultwood
Journal: Blood
Blood (2008) 112 (11): 3642.
https://doi.org/10.1182/blood.V112.11.3642.3642
Published: 2008
Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial

Norbert Gattermann, Mathias Schmid, Matteo Della Porta, Kerry Taylor, John F Seymour, Dany Habr, Gabor Domokos, Abdel Hmissi, Agnès Guerci-Bresler, Christian Rose
Journal: Blood
Blood (2008) 112 (11): 633.
https://doi.org/10.1182/blood.V112.11.633.633
Published: 2008